PRISM BioLab was founded in 2006 by a group of scientists dedicated to creating new drugs based on their technology of peptide mimetic small molecules. More than ten years of research and development has resulted in the clinical pipelines and numerous discoveries of potential seed compounds.
Through its PepMetics® Platform, PRISM has established a proven technology which has already generated successful compounds for what were previously thought to be “undruggable targets”.
Company Name：PRISM BioLab Co.,Ltd
Location：2-26-1, Muraoka-Higashi, Fujisawa, Kanagawa, 251-8555, JAPAN
Director：CEO Dai Takehara